March 26, 2026 - Non-regulatory SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon
March 18, 2026 - Non-regulatory SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25
March 4, 2026 - Non-regulatory Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11
February 6, 2026 - Non-regulatory SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study
